Single lung transplantation for chronic obstructive pulmonary disease: pulmonary function and impact of bronchiolitis obliterans syndrome  by Bjørtuft, Ø. et al.
Respiratory Medicine (1996) 90, 553-559 
Single lung transplantation for chronic obstructive 
pulmonary disease: pulmonary function and impact 
of bronchiolitis obliterans syndrome 
0. BJBRTUFT”~, 0. R. GEIRAN~, J. FJELD~, E. SKOVLUND§, B. JOHANSEN* AND J. BOE* 
Departments of * Thoracic Medicine, TSurgery, and INuclear Medicine, Rikshospitalet, University Hospital 
and $Section of Medical Statistics, University of Oslo, Oslo, Norway 
Chronic obstructive pulmonary disease (COPD) is now the most common indication for single lung 
transplantation. In long-term follow-up, obliterative bronchiolitis is a major problem. The aim of the present 
study was to perform a long-term follow-up of the pulmonary function and to examine the effect of 
development of bronchiolitis obliterans syndrome (BOS). 
Nineteen patients with end-stage COPD underwent single lung transplantation and were followed regularly 
with pulmonary function tests, and ventilation and perfusion scintigraphy (mean observation time 29 
months). They were divided into two categories, with and without BOS, using the definition recommended by 
the International Society for Heart and Lung Transplantation working group. A mixed model analysis of 
variance with BOS as co-variate was used to evaluate its effect on pulmonary function. 
Spirometry, lung transfer factor for carbon monoxide (RCO), arterial blood gases and 6-min walk test 
improved significantly (WO.001) from before transplantation to 3 months after transplantation. Nine patients 
developed BOS. Implied by the definition of the syndrome, forced expiratory volume in 1 s (FEV,) was 
significantly (P<O.OOl) lower for patients with BOS while there was no significant effect of BOS category on 
7’1C0 corrected for alveolar volume (VA) or perfusion to transplant. Patients without BOS maintained their 
pulmonary function, and ventilation and perfusion to transplant for more than 3 yr after transplantation. 
The present results suggest that decreasing FEV, accompanied by an unchanged ~‘LCO/~A and pulmonary 
perfusion support the diagnosis of BOS after single lung transplantation for COPD. 
Introduction syndrome (BOS) is defined as a clinical syndrome 
Chronic obstructive pulmonary disease (COPD) is 
the main indication for single lung transplantation 
(SLT) and now accounts for more than 50% of all 
adult recipients (1,2). Chronic obstructive pulmonary 
disease patients have better actuarial survival (77% 
alive after 1 yr and 62% after 3 yr) than the other 
diagnosis groups (2). Early pulmonary functional 
results of SLT for COPD were very promising (3-5) 
and, recently, medium-term pulmonary function was 
characterized by decreasing values of forced expira- 
tory volume in 1 s (FEV,) with or without pathologic 
evidence of obliterative bronchiolitis (10). Excluding 
other causes of airway obstruction, this definition 
allowed division of the patients into two categories, 
with and without BOS. The aim of the present study 
was to perform a long-term follow-up of the pulmo- 
nary function in COPD patients with SLT and to 
examine the effect of BOS development. 
reported as good (6). 
Obliterative bronchiolitis is a major problem in Methods 
long-term follow-up of lung transplant recipients PATIENTS 
(7-9). According to the recommendations from the 
International Society for Heart and Lung Trans- Single lung transplantation recipients were below 
plantation working group, bronchiolitis obliterans the age of 60 years, suffering from end-stage COPD 
with respiratory failure, and anticipated survival less 
Received 9 September 1995 and accepted in revised form 17 January than 18 months. Between March 1990 and March 
1996. 1994, 19 patients (mean age 51 years, range 40-60 
TAuthor to whom correspondence should be addressed at: Depart- years, six females and 13 males) underwent SLT. The 
ment of Thor&c Medicine, Rikshospitalet, 0027 Oslo, Norway. mean observation time was 29 months. All were 
0954.6111/96/090553+07 $12.0010 0 1996 W. B. Saunders Company Ltd 
554 0. Bjmtuft et al. 
former smokers, and 11 patients had al-antitrypsin 
deficiency. Twelve patients received a right lung and 
seven patients recieved a left lung. Two patients were 
re-transplanted on the contralateral side, one left and 
one right, because of BOS and respiratory failure. 
The peri-operative management and the immunosup- 
pression have been reported previously (11). 
FOLLOW-UP 
The patients were followed-up at the authors’ 
institution regularly and, whenever necessary for 
clinical reasons, with bronchoscopy, bronchoalveolar 
lavage and transbronchial biopsies to exclude other 
causes of airway obstruction than BOS (12). Spirom- 
etry and gas-diffusing capacity measurements were 
performed at 1, 2, 3, 4 and 6 months post-operatively 
and every 6 months thereafter. Ventilation and per- 
fusion scintigraphy, arterial blood gases and 6-min 
walk test were performed at 1, 3, 6, 12, 24 and 36 
months post-operatively. Sometimes the patients 
were unable to perform the tests or the results were 
unsuitable for reasons such as simultaneous infection 
or rejection. In such cases, results from a stable 
period close to the actual symptomatic episode (l-2 
months before or after) were used if available. 
In accordance with the recommendations from the 
International Society for Heart and Lung Transplan- 
tation working group (lo), the baseline value for 
FEV, was defined. The consecutive FEV, values were 
expressed as a percentage of this baseline value to 
determine the patients’ BOS stage at every follow-up 
after 3 months. Hence, the patients at Stage 0, i.e. 
with an FEV, 80% or more of the baseline value, 
were categorized as Non-BOS, and the patients at 
Stages 1, 2 or 3, i.e. with an FEV, below 80% of 
baseline value, were categorized as BOS. Patients 
could change from Non-BOS to BOS and back again 
over time. As a result, there were no constant groups 
of BOS or Non-BOS patients; some patients died or 
underwent re-transplantation, while new patients 
developed BOS. Re-transplanted patients were 
excluded following re-transplantation. At 6 months, 
it was possible to categorize the patients into BOS 
and Non-BOS groups, allowing comparison of pul- 
monary function in these two separate groups before 
transplantation as well as 3 and 6 months post- 
transplant. 
PULMONARY FUNCTION TESTS 
Dynamic lung volumes and lung transfer factor for 
carbon monoxide (TLCO) were measured using an 
automated pulmonary function unit (Gould 2400, 
Sensormedics, Bilthoven, The Netherlands). This 
unit has a pneumotachygraph which measures flows 
and integrates them to volumes. The system was 
calibrated daily. The software complies with the 
recommendations issued by the American Thoracic 
Society (13). The patients were examined in the 
sitting position wearing a noseclip. At least three 
satisfactory trials were performed. The highest forced 
vital capacity (FVC) and FEV, were recorded. 
7’1C0 was measured with the single breath tech- 
nique (14) and according to recommended guidelines 
(15). The test gas consisted of 0.3% carbon monoxide 
(CO), 10% helium (He), 19% oxygen and a balance of 
nitrogen. The patients inhaled the test gas from 
residual volume, held their breath for approximately 
10 s and exhaled. The first 750 ml of the expiratory 
sample was discarded, and the rest was collected in a 
bag and analysed with respect to CO and He concen- 
trations. Effective alveolar volume (VA) was calcu- 
lated from the dilution of He, and corrected for 
carbon dioxide absorption. The transfer coefficient 
was calculated as TLCO/Va. The average of two 
measurements was recorded. Values were corrected 
for haemoglobin, but not for altitude or carboxy- 
haemoglobin. Reference values for all lung function 
variables were those of European Community for 
Steel and Coal (15). 
Arterial blood samples were obtained from the 
radial artery for the measurement of arterial 0, 
(PaO,) and arterial CO, (PaCO,) tension with the 
patients resting and breathing room air. 
EXERCISE TESTING 
The patients performed a standardized 6-min walk 
test (16). They were instructed and encouraged to 
walk as fast and as long as possible in the hospital 
corridor for 6 min. They could stop and rest at any 
time, but the resting time was included in the 6 min. 
One patient was unable to perform the 6-min walk 
test properly. This set of results is excluded because 
he had a hip fracture 1 month post-operatively, and 
later needed insection of a hip prosthesis. 
QUANTITATIVE VENTILATION AND PERFUSION 
SCINTIGRAPHY 
Ventilation studies 
Until January 1993, the ventilation studies were 
performed with lz7Xe. Wearing a noseclip, the 
patients ventilated from a spirometer. The spirometer 
was filled with oxygen and about 40 MBq lz7Xe 1~ i 
oxygen was added. With their back against the 
gamma camera, the patients ventilated in this closed 
system for 67 min, while the CO, was absorbed in a 
calcium-hydroxide filter. A gamma camera (General 
Electric 400 AZS) with a medium energy and medium 
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resolution collimator was used. From regions of 
interest (ROI) drawn around each lung when steady 
state was reached, the gamma camera counts for each 
lung were recorded. The ventilation of each lung was 
expressed as a percentage of the total counts in both 
lungs. From January 1993, the Technega@ (Tetley 
Manufacturing Ltd, Sydney, Australia) ventilation 
system was used, along with a new gamma camera 
(Elscint Apex SP-GHR). The system was loaded with 
300-400 MBq 99mT~ pertechnetate in a 0.1 ml elution 
volume from an IFETEC 99mT~ generator (Institutt 
for Energiteknikk, Norway). With the patient in 
the supine position, and the camera in the dorsal 
position, one to three deep inhalations from the 
TechnegasO system were performed, until a count 
rate of 2000 counts s - i was achieved, corresponding 
to a total inhaled activity of about 30 MBq. With the 
camera in the dorsal position, the scintigraphic aqui- 
sition was started immediately after the inhalation, 
and continued until a picture with 250 000 counts 
was obtained. Thereafter, using the same acquisition 
time as in the dorsal view, scintigrams from the 
anterior and from the four oblique views were taken. 
The ventilation of each lung was expressed as a 
percentage of the total counts in both lungs, using the 
arithmetic mean of the counts in the anterior and 
posterior views. 
Perfusion studies 
Macro-aggregated albumin (IFE MAA, Institutt 
for Energiteknikk, Norway) was labelled with 99mT~ 
and an intravenous dose of 180 MBq in about 1 ml 
was administered during 1 min with the patient in the 
supine position, breathing in and out slowly and 
deeply. With the camera in the dorsal position, the 
registration was started immediately after the injec- 
tion, and continued until a picture with 500 000 
counts was obtained. Thereafter, using the same 
acquisition time as in the dorsal view, scintigrams 
from the anterior and from the four oblique views 
were taken. The perfusion of each lung was expressed 
as a percentage of the total counts in both lungs, 
using the arithmetic mean of the counts in the 
anterior and posterior views. 
STATISTICAL ANALYSIS 
A mixed model analysis of variance (17) was used 
to evaluate the effect of BOS on FEV,, ~CO/VA and 
perfusion. The model was: 
where ,U is the overall mean, ai is the effect of time 
(fixed), bi is the effect of patient (random), 6 is the 
coefficient of the covariate (BOS category), xiik is the 
covariate value (0 or 1) and E+ is the error term. 
On each occasion, it was decided whether a patient 
was BOS (coded 1) or Non-BOS (coded 0). Different 
BOS stages were not included due to the small 
number of patients. A two-tailed Students’ t-test was 
used to compare pulmonary function tests before 
transplantation and 3 months after transplantation. 
Results 
Eight patients developed serious and chronic prob- 
lems and five of them died, while two patients were 
re-transplanted (Table 1). Fourteen patients are alive 
12-60 months after transplantation. The two 
re-transplanted patients have excellent lung function 
(FEV, 61 and 65% of predicted) 20 and 8 months 
after re-transplantation. Eleven patients experienced 
only minor or treatable complications and are alive 
and well at home. However, four of them have 
developed BOS, but this has not yet affected their 
daily life. A total of nine patients (47%) have thus 
met the criteria of BOS. The five BOS patients with 
severe BOS, Stage 3, also developed respiratory fail- 
ure. This end-stage period was often short and did 
not always coincide with scheduled follow-up times, 
and these patients were sometimes unable to perform 
the pulmonary function tests. Consequently, of the 
19 measurements in the BOS group, BOS Stages 1, 2 
and 3 were diagnosed seven, nine and three times, 
respectively. 
PULMONARY FUNCTION AND EXERCISE TEST 
The results of spirometry, gas diffusing capacity, 
arterial blood gases and 6-min walk test before 
transplantation, and 3 and 24 months after trans- 
plantation, are shown in Table 2. Pulmonary func- 
tion improved significantly (P<O.OOl) from before 
transplantation to 3 months after transplantation in 
all tests. Table 3 shows the development of gas 
diffusing capacity for patients developing BOS and 
the different stages of BOS. Figure. 1 reveals the 
development of FEV, in percent of predicted com- 
pared with RCO/VA in % predicted in the two 
groups. In a mixed model analysis of variance with 
BOS as co-variate, a highly significant effect of BOS 
category was found. The estimated reduction in 
FEV, (% predicted) was 13.7 with a standard error of 
2.7 (P<O.OOl). The effect of BOS category on 
ItCOlvA was not statistically significant (it was 
estimated to an increase of 2.4 with s~=5.7). There 
was no significant difference between measurements 
obtained at different times from transplant. 
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Table I The outcome for eight patients with serious complications after transplantation 
Transplant 
no. 
Date of transplant/ 
sex/age Event (months after transplant) 
1 
2 
5 
6 
13 
14 
15 
18 
3-90/M/41 
5-90/F/52 
11-91/M/58 
12-91/M/40 
11-92/F/48 
1-93/M/49 
1-93/M/55 
10-93/M/54 
BOS (6). Re-transplantation on the contralateral side (40). Excellent result, 
alive, well and working part-time (60). 
Died unexpectedly of acute pancreatitis (57). 
Died of malignant melanoma (8) transmitted from the donor. 
BOS (8). Died of respiratory failure (16). Obliterative bronchiolitis verified 
at autopsy. 
BOS (12). Re-transplanted on the contralateral side (19). Excellent result, 
alive, well and working full-time (27). 
BOS (6). Continued to decrease in lung function and accepted for 
re-transplantation (22). 
BOS (6) with respiratory failure and liver failure. Assessed for 
re-transplantation. Died of intra-abdominal bleeding after liver biopsy 
(10). Obliterative bronchiolitis verified at autopsy. 
Necrosis and infection in the anastomosis postoperatively. Died of massive 
haemoptysis (2). 
BOS, bronchiolitis obliterans syndrome. 
Table 2 Spirometry, lung transfer factor for carbon monoxide, arterial blood gases and 6-min walk test for all patients 
before transplantation, and 3 and 24 months after transplantation 
Time No. 
FVC 
WI 
FEV, 
(%I 
TLC0 
WI PaO, PaCO, 
6-min 
walk test 
Before 19 1.77 f 0.90 0.54 * 0.22 1.91 * 1.1 0.50 f 0.26 7.1 Lt 1.3 6.9 f 2.2 187zk 101 
(41 zt 19) (16 * 6) (2Ok 10) (26& 13) 
3 months 18 2,52z!zO,86 1-52 * 0.42 5.9 zk 2.4 1.46rtO49 10.0 * 1.5 5.1 Yt 0.4 498zk128 
(63 f 16) (46 * 7) (62520) (75 *26) 
24 months 12 2.25 f 0.40 1.24 f 0.27 5.9 i 2.0 1.67 zt 0.42 10.1 * 1.5 5.3 zt 0.4 556zk53 
(59 f 10) (40 f 13) (63 zk 17) (87h23) 
No., number of patients; FVC, forced vital capacity in (1); FEV,, forced expiratory volume in 1 s (1); TACO, single breath 
lung transfer factor for carbon monoxide (mmol kPa min - r); TLCO/VA, ZLCO/alveolar volume; PaO, and PaCO,, arterial 
0, and CO, tension (kPa); and 6-min walk test (m). Percentage of predicted in brackets. All values in mean f SD. 
VENTILATION AND PERFUSION SCINTIGRAPHY Discussion 
Before transplantation, all the scintigrams revealed 
uneven but matched ventilation (V) and perfusion 
(Q) distribution, consistent with severe COPD. In the 
transplanted lung, the distribution of V and Q was 
even and normal provided the lung function was 
stable. When FEV, declined, reflecting development 
of BOS, an uneven distribution of V re-appeared in 
the transplanted lung. Compared with the pre- 
operative situation, the relative distribution of V and 
Q showed a persistent shift towards the transplanted 
side (Fig. 2). Using the same statistical model as 
above, but with perfusion as the response variable, 
no significant effect of BOS category on perfusion 
and no changes over time were found (Fig. 3). 
Histological verification of the diagnosis of 
obliterative bronchiolitis is a major problem (18). 
Although the clinical picture is often characteristic 
with a gradual onset of dyspnoea and decreasing 
FEV,, no uniform definition of clinical oblitera- 
tive bronchiolitis has existed. It has thus been 
difficult to classify the clinical status and compare 
data from different studies. The recommendations 
from the International Society for Heart and 
Lung Transplantation working group (10) on BOS 
represent a major step forward when it comes 
to studying the development of the syndrome at 
an early stage and preventing progression of the 
disease. 
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Table 3 Lung transfer factor for carbon monoxide, TLCOITLCOIVA, for all patients 
developing bronchiolitis obliterans syndrome 
Transplant 
Months after transplantation 
no. Before 3 6 12 24 36 48 
1 106/133 95/120t 64/102”r 58/94'r 42/90$ 851935 
3 14/13 66161 65172 79194 87194 75/101* ss/sst 
4 35142 56159 65B3" 51163 62176" 69/88* 44/66t 
6 76/88 701741 
9 7113 58l58 66173 55/70-f 68/811 
12 41150 49168 56163 47/77t 
13 13127 32167 29171 50/s4t 661905 
14 23125 53159 63168" 68/70* 271421 
15 24140 44183 36/86* 
TACO, lung transfer factor for carbon monoxide; TLCOI~A, TLC0 corrected for alveolar 
volume (VA) in percent of predicted. When the patients fulfill the criteria for bronchiolitis 
obliterans syndrome (BOS) and are included in the BOS group (see text), their values are 
written in bold. BOS stages are indicated by *Stage 1, tStage 2 and $Stage 3. 5 indicates values 
after re-transplantation.- 
In obliterative bronchiolitis associated with lung 
transplantation, little emphasis has been placed on 
gas diffusing capacity measurements. In an early 
study of five heart-lung transplant recipients who 
developed airway obstruction, FEV, ranged from 18 
to 53% of predicted, while 7X0 was higher in every 
case, range 44-69%. The RCO/I’A values were not 
presented (19). In a review of obliterative bronchio- 
litis in 1990, gas diffusing capacity is not mentioned 
(20) and, in a recent review, nCO/Va is claimed to 
be reduced without presenting data or references (7). 
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Fig. I Lung transfer factor for carbon monoxide corrected 
for alveolar volume (TLCO/VA) and forced expiratory vol- 
ume in 1 s (FEV,) in the Non-BOS and BOS groups (see 
text). The number at the value points is the number of 
patients in the groups at that time. 0, TLCOIVA Non-BOS; 
0, TLCOWA BOS; A, FEV, Non-BOS; 0, FEV, BOS. 
Obliterative bronchiolitis and a BOS-like clinical 
state often develops following bone marrow trans- 
plantation. A detailed study of 29 such patients 
revealed well-preserved TTtCO/Va (21). In a com- 
parative study of bone marrow and lung transplant 
patients developing bronchiolitis obliterans, the clini- 
cal picture is similar and ~‘LCOIVA is normal (22). 
However, only one of nine lung transplant patients in 
this study was single lung transplanted. Obliterative 
bronchiolitis not associated with organ transplanta- 
tion is a rare disease in which TLCO/VA is usually 
normal (22-25). These observations correspond with 
the results in the present study; patients with mild to 
.$ 20 1 
3 
Fr 0 ’ I I 
21 3 6 1; J 'k? 36 
a 
2 
Time since transplantation (months) 
Fig. 2 Ventilation (0) and perfusion (0) to transplanted 
side as a percentage of total. The number at value points is 
number of patients at that time. 
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Fig. 3 Perfusion to transplanted side as a percentage of 
total in the Non-BOS (0) and BOS (0) groups (see text). 
moderate BOS had unchanged TLCO/~A. However, 
one patient (Table 3, Patient 1) displayed a clear 
decrease in 7X0 and ~‘LCOIVA during the obser- 
vation period. Even so, with advanced BOS at 36 
months, he had remarkably well-preserved TLC0 
and TLCOI~A, while his FEV, was only 12% of 
predicted. In advanced BOS, the authors’ data is 
scarce, but indicates reduced TLC0 and ~LCO/VA. 
In the present study, 7X0/ VA increased through- 
out the first year in contrast to spirometry and 
ventilation and perfusion which usually reached the 
highest value during the first 6 months. These RCO 
values correspond to TLC0 after SLT for pulmonary 
fibrosis (before transplantation 36%, at 3 months 
after surgery 58% and at 12 months 62% of predicted, 
mean results from nine patients) (26). On the other 
hand, FEV, in fibrosis patients was about 50% 
pre-operatively and 73% at 3 months after transplan- 
tation (27), but only 16% and 46% in the present 
study, in accordance with other studies (4,6). The 
difference in pulmonary physiology between restric- 
tive and obstructive diseases can explain the differ- 
ences in FEV, values between the fibrosis and COPD 
patients. 
Serious ventilation and perfusion imbalance was 
reported in the early attempts with SLT for emphy- 
sema (28). When the Toronto Lung Transplant 
Group in 1986 reported that SLT was successful for 
pulmonary fibrosis patients, they considered SLT to 
be unsuitable for emphysema patients (29,30). How- 
ever, in recent reports of SLT for emphysema, there 
is an immediate and, in the first months, persistent 
distribution of V and Q towards the transplanted 
lung, but still a certain V/Q mismatch (11,31,32). 
These promising results are confirmed in the present 
study, also demonstrating that this initial V/Q rela- 
tionship continues for more than 3 yr. Development 
of mild to moderate BOS does not appear to affect 
the perfusion in the transplanted lung. Unfortu- 
nately, the authors were unable to assess the effect of 
BOS on ventilation because of methodological prob- 
lems. The Technegasa method was inappropiate for 
measuring the fraction between the two lungs 
because the native lung contained areas with high 
counts of activity, ‘hot spots’, probably as a result of 
turbulent air flow. Consequently, as the ventilation 
method was changed from xenon to Technega@ 
after January 1993, the fraction to the native lung 
was overestimated for the patients at 24 months and 
36 months. 
The present study confirms that patients without 
bronchiolitis obliterans syndrome obtain good and 
constant pulmonary function, and acceptable and 
persistent ventilation and perfusion to transplant for 
more than 3 yr after single lung transplantation. 
However, nearly 50% of these patients developed 
BOS and more than 25% developed respiratory fail- 
ure because of BOS, thus emphasizing that BOS is 
the main problem in long-term follow-up after SLT. 
These results suggest that a decreasing FEV, 
accompanied by an unchanged TLCO/VA supports 
the diagnosis of BOS. 
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